Tyme Technologies, Inc. (TYME) Stock Analysis
DELISTED 2022
What happened to Tyme Technologies, Inc. (TYME) stock?
Tyme Technologies, Inc. (TYME) no longer trades on public markets. It was delisted in September 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tyme Technologies, Inc. (TYME) trades at $0.3107. Tyme Technologies, Inc. is a biotechnology company focused on developing cancer metabolism-based therapies (CMBTs). Their lead drug product, SM-88, is undergoing clinical trials for various cancer types. Sector: Healthcare.
Last analyzed: May 9, 2026Analyst Coverage for TYME: TYME does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TYME against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
TYME: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Tyme Technologies, Inc. (TYME) Healthcare & Pipeline Overview
Tyme Technologies, Inc., a biotechnology firm, is dedicated to the creation of cancer metabolism-based therapies, with its primary focus on SM-88, a CMBT currently undergoing Phase II/III clinical trials across a spectrum of 15 cancer types. The company also explores treatments for SARS CoV-2 and inoperable tumors.
What Is the Investment Thesis for TYME?
Tyme Technologies, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cancer metabolism-based therapies (CMBTs) offers a novel approach to cancer treatment, potentially addressing limitations of traditional therapies. The primary value driver is the successful completion of Phase II/III clinical trials for SM-88 across multiple cancer types. Positive clinical data and subsequent regulatory approval could lead to significant market adoption and revenue generation. However, the company's reliance on a single lead drug candidate and the inherent risks associated with clinical development pose substantial challenges. The company's status as a subsidiary of Spyre Therapeutics, Inc. introduces both potential synergies and dependencies. Investors should carefully weigh the potential for breakthrough innovation against the significant clinical and regulatory hurdles.
Based on FMP financials and quantitative analysis
TYME Key Highlights
SM-88 is in Phase II/III clinical trials, targeting a wide array of cancers, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon cancers.
- Tyme Technologies has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment.
- TYME-19, an oral synthetic member of the bile acid family, is in preclinical stage for the treatment of SARS CoV-2 diseases.
- TYME-18, a CMBT compound, is in preclinical stage for the treatment of inoperable tumors.
- Tyme Technologies, Inc. operates as a subsidiary of Spyre Therapeutics, Inc. as of September 16, 2022.
Who Are TYME's Competitors?
TYME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $107.79 | -1.04% | $9.36B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TYME's Key Strengths?
Novel cancer metabolism-based therapy (CMBT) approach.
- Lead drug candidate (SM-88) in Phase II/III clinical trials.
- Research collaborations with Mayo Clinic and Georgetown University.
- Pipeline of preclinical assets targeting cancer and infectious diseases.
What Are TYME's Weaknesses?
Reliance on a single lead drug candidate (SM-88).
- High risk of clinical trial failure.
- Limited financial resources.
- Dependence on Spyre Therapeutics, Inc.
What Could Drive TYME Stock Higher?
Completion of Phase II/III clinical trials for SM-88 in pancreatic cancer.
- Data readouts from ongoing clinical trials of SM-88 in other cancer types (prostate, breast, lung, etc.) expected in Q3 2026.
- Progress in preclinical development of TYME-19 for SARS-CoV-2 treatment.
- Advancement of TYME-18 for inoperable tumors.
What Are the Key Risks for TYME?
Negative return on equity (-23.8%) — the business is not currently generating profit on shareholder capital.
- Failure of SM-88 to demonstrate efficacy in Phase II/III clinical trials.
- Regulatory delays or rejection of SM-88 by the FDA.
- Competition from other pharmaceutical companies developing cancer therapies.
- Dependence on Spyre Therapeutics, Inc. for funding and resources.
- Patent challenges to Tyme Technologies' intellectual property.
What Are the Growth Opportunities for TYME?
- Expansion of SM-88 into new cancer indications: Tyme Technologies has the opportunity to expand the use of SM-88 into additional cancer types beyond the current Phase II/III trials. This would involve conducting further clinical trials to demonstrate efficacy and safety in these new indications. The market size for each new indication could be substantial, potentially adding significant revenue streams. The timeline for this growth opportunity depends on the successful completion of ongoing trials and the initiation of new clinical programs. Success hinges on demonstrating the broad applicability of CMBTs across diverse cancer types.
- Advancement of TYME-19 for SARS-CoV-2 treatment: The development of TYME-19 as a treatment for SARS-CoV-2 diseases represents a significant growth opportunity for Tyme Technologies. While the pandemic has subsided, the need for effective antiviral therapies remains. Successful preclinical and clinical development of TYME-19 could lead to a valuable product in the infectious disease market. The timeline for this opportunity depends on the progress of preclinical studies and the initiation of clinical trials. The market size will depend on the future prevalence and severity of SARS-CoV-2 infections.
- Development of TYME-18 for inoperable tumors: The preclinical development of TYME-18 for the treatment of inoperable tumors presents another growth avenue for Tyme Technologies. Inoperable tumors represent a significant unmet medical need, and effective therapies could command substantial market value. The timeline for this opportunity depends on the successful completion of preclinical studies and the initiation of clinical trials. The market size will depend on the specific types of inoperable tumors targeted and the clinical efficacy of TYME-18.
- Strategic partnerships and collaborations: Tyme Technologies can pursue strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its products. These partnerships could provide access to additional funding, expertise, and market reach. The timeline for this opportunity is ongoing, as the company can actively seek out and negotiate partnerships at any time. The potential impact on growth will depend on the specific terms and scope of the partnerships.
- Geographic expansion: Tyme Technologies could explore opportunities to expand its operations and commercialize its products in international markets. This would involve conducting clinical trials and seeking regulatory approvals in different countries. The timeline for this opportunity depends on the company's strategic priorities and the regulatory landscape in each target market. The potential market size will vary depending on the specific geographic regions targeted and the prevalence of cancer in those regions.
What Are TYME's Competitive Advantages?
- Proprietary cancer metabolism-based therapy (CMBT) technology platform.
- Patent protection for CMBT drug candidates and methods of use.
- Clinical data demonstrating the efficacy and safety of CMBTs.
- Research collaborations with leading institutions like Mayo Clinic and Georgetown University.
What Does TYME Do?
Tyme Technologies, Inc., established in 2011 and formerly known as Global Group Enterprises Corp., is a biotechnology company committed to pioneering cancer metabolism-based therapies (CMBTs). The company's core focus revolves around the development and commercialization of novel therapies designed to disrupt the metabolic pathways of cancer cells, offering a potentially less toxic and more effective approach to cancer treatment. Their lead drug product, SM-88, is a CMBT currently in Phase II/III clinical trials, targeting a wide array of cancers, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon cancers. This broad-spectrum approach reflects the company's belief in the potential of CMBTs to address multiple cancer types by targeting fundamental metabolic vulnerabilities common across different malignancies. In addition to SM-88, Tyme Technologies is also advancing a pipeline of preclinical assets, including TYME-19, an oral synthetic member of the bile acid family being investigated for the treatment of SARS CoV-2 diseases, and TYME-18, a CMBT compound in preclinical development for the treatment of inoperable tumors. These programs underscore the company's commitment to expanding its therapeutic reach and addressing unmet medical needs in both oncology and infectious diseases. Tyme Technologies has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
What Products and Services Does TYME Offer?
- Develop cancer metabolism-based therapies (CMBTs).
- Conduct clinical trials to evaluate the safety and efficacy of CMBTs.
- Research and develop new CMBT drug candidates.
- Collaborate with research institutions and universities to advance CMBT research.
- Seek regulatory approvals for CMBT products.
- Potentially commercialize and market approved CMBT products.
How Does TYME Make Money?
- Develop and patent novel cancer metabolism-based therapies (CMBTs).
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Potentially manufacture and sell approved CMBT products directly.
- Generate revenue through research grants and collaborations.
What Industry Does TYME Operate In?
Tyme Technologies, Inc. operates within the competitive biotechnology industry, characterized by intense research and development, high regulatory hurdles, and significant financial investments. The company's focus on cancer metabolism-based therapies (CMBTs) positions it within a growing segment of the oncology market that seeks to address the limitations of traditional chemotherapy and radiation. The industry is driven by increasing cancer prevalence, advancements in personalized medicine, and the demand for more effective and less toxic treatments. Tyme Technologies faces competition from established pharmaceutical companies and other biotechnology firms developing novel cancer therapies. The success of the company depends on its ability to demonstrate clinical efficacy, secure regulatory approvals, and effectively commercialize its products.
Who Are TYME's Key Customers?
- Cancer patients in need of new treatment options.
- Oncologists and other healthcare professionals who treat cancer patients.
- Pharmaceutical companies seeking to acquire or license novel cancer therapies.
- Research institutions and universities interested in collaborating on CMBT research.
Company Profile
Tyme Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Steven E. Hoffman. TYME has traded publicly since 2012.
Key Financial Metrics
Return on equity for Tyme Technologies, Inc. stands at -23.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -24.6%, showing how much profit it generates from its asset base. A current ratio of 10.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.5%, the inverse of the P/E and a quick read on earnings relative to price.
TYME Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has turned positive recently, with discussions highlighting the innovative approaches Tyme is taking in the biotech sector.
- Recent announcements about advancements in their lead product have generated excitement among investors, reflecting a growing belief in its market viability.
- The overall market perception of biotech companies has been improving, and Tyme is seen as a player that could benefit from this trend.
Bear Case
- Concerns about the company's financial health persist, with ongoing questions around its ability to fund operations without significant revenue streams.
- Recent social sentiment has shown some skepticism, with discussions focusing on the risks associated with clinical trials and regulatory hurdles.
- Market perception remains cautious as investors weigh the competitive landscape and Tyme's position within it, leading to a bearish outlook for some.
- Insider selling activity in the past raised red flags, suggesting that some insiders may not be as optimistic about the near-term future of the company.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TYME Latest News
No recent news available for TYME.
Leadership: Steven E. Hoffman
Chief Executive Officer
Steven E. Hoffman has served as CEO of Tyme Technologies, Inc. since 2015. He brings extensive experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and commercialization. Prior to joining Tyme Technologies, Mr. Hoffman held leadership positions at several pharmaceutical companies, including executive roles at companies focused on oncology and drug delivery systems. His experience includes overseeing clinical development programs, managing regulatory submissions, and leading commercial launch activities. He has a strong background in finance and operations, with a proven track record of driving growth and creating shareholder value.
Track Record: Under Mr. Hoffman's leadership, Tyme Technologies has advanced its lead drug candidate, SM-88, into Phase II/III clinical trials across multiple cancer types. He has also overseen the expansion of the company's preclinical pipeline and the establishment of research collaborations with leading institutions. Key milestones include securing orphan drug designation for SM-88 and raising capital to support clinical development activities. He manages 13 employees.
What Investors Ask About Tyme Technologies, Inc. (TYME) — Healthcare
What happened to Tyme Technologies, Inc. (TYME) stock?
Tyme Technologies, Inc. (TYME) no longer trades on public markets. It was delisted in September 2022. The figures below are historical and are not a current quote.
Can I still buy TYME shares?
No. TYME stopped trading on public markets in September 2022, so the shares are not available through a broker. Anything you see quoted for TYME elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TYME stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Tyme Technologies, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Tyme Technologies, Inc. do?
Tyme Technologies, Inc. is a biotechnology company focused on developing cancer metabolism-based therapies (CMBTs). Their lead drug product, SM-88, is a CMBT currently in Phase II/III clinical trials, targeting a wide array of cancers, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon cancers.
What do analysts say about TYME stock?
Analyst coverage of Tyme Technologies, Inc. is limited due to its market capitalization and stage of development. However, analysts generally acknowledge the potential of the company's cancer metabolism-based therapy (CMBT) approach. Key valuation metrics are difficult to assess at this stage, as the company is pre-revenue and heavily reliant on clinical trial outcomes.
What are the main risks for TYME?
The main risks for Tyme Technologies, Inc. include the potential failure of SM-88 to demonstrate efficacy in Phase II/III clinical trials, regulatory delays or rejection of SM-88 by the FDA, competition from other pharmaceutical companies developing cancer therapies, dependence on Spyre Therapeutics, Inc. for funding and resources, and patent challenges to Tyme Technologies' intellectual property.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.